- Home
- LYEL vs KIO Comparison
LYEL vs KIO Comparison
Compare LYEL & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LYEL | KIO |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 470.1M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | LYEL | KIO |
|---|---|---|
| Price | $22.27 | $11.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 95.9K | ★ 258.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $10.69 |
| 52 Week High | $45.00 | $12.83 |
Technical Indicators
Market Signals| Indicator | LYEL | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 31.53 |
| Support Level | $21.27 | N/A |
| Resistance Level | $27.30 | $12.15 |
| Average True Range (ATR) | 2.12 | 0.09 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 26.16 | 25.32 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.